Toll To Be Paid at the Gateway to the Vessel Wall
2005; Lippincott Williams & Wilkins; Volume: 25; Issue: 6 Linguagem: Inglês
10.1161/01.atv.0000168894.43759.47
ISSN1524-4636
AutoresGöran K. Hansson, Kristina Edfeldt,
Tópico(s)Inflammasome and immune disorders
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 25, No. 6Toll To Be Paid at the Gateway to the Vessel Wall Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBToll To Be Paid at the Gateway to the Vessel Wall Göran K. Hansson and Kristina Edfeldt Göran K. HanssonGöran K. Hansson From the Center for Molecular Medicine and Department of Medicine, Karolinska Institute, Stockholm, Sweden. and Kristina EdfeldtKristina Edfeldt From the Center for Molecular Medicine and Department of Medicine, Karolinska Institute, Stockholm, Sweden. Originally published1 Jun 2005https://doi.org/10.1161/01.ATV.0000168894.43759.47Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1085–1087The innate immune defense is ready to combat invading microbes whenever they invade our inner territories. Innate immunity consists of soluble molecules and cell-bound receptors, all of which are encoded in the germline DNA. This contrasts with the adaptive immune system, the molecular components of which are generated by somatic rearrangement processes. In atherosclerosis research, much interest has been focused on a soluble component of innate immunity, the acute phase protein C-reactive protein (CRP). Other members of the innate immune family are also involved in the atherosclerotic process, including the complement cascade, the antimicrobial peptides, and the pattern recognition receptors (PRR).See pages 1213 and 1220The large group of PRRs contains several families of receptors. Their common denominator is a broad specificity with a capacity to bind many different macromolecules produced by invading microbes. The first PRRs to be discovered were the scavenger receptors (ScR), which were identified as transmembrane receptors binding lipopolysaccharide (LPS) of endotoxins, acetylated LDL, and certain polynucleotides. Michael Brown and Joseph Goldstein discovered ScR in 1979,1 and the first one of them, SR-A, was cloned in 1990.2The next step in PRR discovery came from an entirely different line of research. Christiane Nüsslein-Volhard of the Max Planck Institute in Tübingen analyzed mutations in fruit flies. In 1985, she saw a weird-looking fly larva in which the ventral portion of the body was underdeveloped. Her spontaneous comment was "Das war ja toll!" meaning "That was weird!" and she coined the name Toll for the mutated gene. The protein product of the Toll gene was found to cause ventralization, and normal functional activity of Toll is necessary for dorsoventral polarity in the fly. The discovery of Toll was one in a series of discoveries of genes controlling early embryogenesis, which led to a Nobel prize for Nüsslein-Volhard in 1995.A decade after Nüsslein-Volhard's discovery of Toll, Jules Hoffmann's laboratory in Strasbourg reported that Toll not only controls dorsoventral polarity but also has a role in the immune defense in Drosophila.3 Without Toll, flies did not survive fungal infection. Interestingly, Toll activation triggered an NF-κB cascade, which mounted the defense against fungi. It was already known that Spätzle, the protein that induces ventralization by binding to Toll, elicits an NF-κB cascade.4 With Hoffmann's discovery, Toll was, for the first time, associated with host defense.Was there a mammalian equivalent of this defense protein in the fruit fly? Ruslan Medzhitov and Charles Janeway at Yale University were the first to report the cloning of a mammalian homologue, a Toll-like receptor (now called TLR4).5 Its ligand remained unknown. However, by constructing a constitutively active mutant, Medzhitov et al could determine that TLR induces NF-κB activation in a similar way as ligation of the interleukin (IL)-1 receptor—and similarly to Drosophila Toll. The Figure displays the signal transduction pathway for mammalian TLR4. Download figureDownload PowerPointSchematic view of the TLR4-induced signal transduction pathway. Ligands bind to the CD14-TLR4 complex, which is linked to a chain of transducing proteins including MyD88 and IRAK. TRAF6 conveys the signal to a complex that activates the MAP kinase cascade, which ends on the transcription factor AP-1. In parallel, the TRAF6 mediated signal activates Iκ kinase (IKK), leading to phosphorylation, ubiquitination, and degradation of IκB and the nuclear translocation of the transcription factor NF-κB.How could mammalian TLR participate in host defense? Does it bind a "danger molecule" produced by the host on infection? Or a microbial molecule released from the pathogen? This important question was answered by Alexander Poltorak and Bruce Beutler in Dallas, who discovered that TLR4 is the long-sought receptor for LPS, the active component in endotoxin from Gram-negative bacteria.6 With this finding, it became obvious that TLRs constitute a family of pattern recognition receptors, which ligate "pathogen-associated molecular patterns." The existence of such receptors had been predicted by Charles Janeway several years earlier, but their nature had remained enigmatic.7Since these fundamental discoveries, the TLR family of pattern recognition receptors have become a major component in innate immunity, innate-adaptive crosstalk, infectious diseases, and inflammatory conditions. Not surprisingly, TLRs are also involved in cardiovascular diseases. TLR ligation on endothelial cells is a key step in septic shock.8 Through TLR4, circulating LPS initiates an NF-κB signal that leads to nitric oxide production, vasodilation, and hypotensive shock. Ligation of TLR2 by Gram-positive bacteria may cause a similar reaction, and inflammatory activation can also be induced when bacterial unmethylated CpG DNA binds TLR9.9Several reports over the last 4 years show that TLRs may also be involved in atherosclerosis. The entire spectrum of TLRs is expressed by macrophages and endothelial cells of human atherosclerotic plaques,10 and TLR4 may be particularly important because it is expressed by macrophages and upregulated by oxidized LDL.11 Mildly oxidized (minimally modified, mm) LDL binds to CD14, a glycophosphatidylinositol anchored cell surface protein; the mmLDL-CD14 complex binds to TLR4 and triggers a cellular response in the macrophage.12 In addition to mmLDL, TLR4 also binds heat shock protein-60, another antigenic protein implicated in atherosclerosis.13Several lines of evidence suggest that TLR ligation is proatherogenic. Mice lacking TLR4 develop smaller neointimal lesions after vascular injury,14 and TLR2 has similar effects.15 Two studies of hypercholesterolemic apoE−/− mice show that a defect in the TLR-associated signal transduction protein, MyD88, reduces atherosclerosis,16,17 and the absence of TLR4 itself also reduces disease in such mice.17 Interestingly, the effect of homozygous TLR4 deficiency was only 24% in the study by Michelsen et al, while homozygosity for a targeted MyD88 allele was 57%.17 Of note, MyD88 transduces signals not only from TLRs but also from the IL-1 and IL-18 receptors, both of which are involved in proatherogenic signaling.18,19 In addition, both studies were performed using fat-fed apoE−/− mice, which develop excessive hypercholesterolemia, extremely rapid atherosclerosis, and immunologic perturbations,20 all of which could mask more subtle modifying effects of specific receptors.It is evident from several studies that TLR ligation induces inflammatory mediator release, and it may impact on atherosclerosis by promoting inflammatory activity in the plaque. However, recent studies reveal that metabolic effects must also be considered. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Kazemi et al show that TLR ligation directly affects lipid accumulation in macrophages.21 They treated RAW 264.7, a mouse macrophage line, with ligands for TLR2, TLR3, and TLR4. Both zymosan, a TLR2 ligand, and LPS, which binds to TLR4, increased expression of adipocyte fatty acid–binding protein (aP2) and caused accumulation of cholesteryl ester and triglyceride in the cells. By assisting with the transport of fatty acids needed for cholesteryl esterification and triglyceride accumulation, aP2 promotes intracellular lipid accumulation in differentiated adipocytes and also in lipid-loaded macrophages. This process is important for atherosclerosis, because aP2 deficiency reduces lesion formation and progression in genetically hypercholesterolemic mice.22–24 The new report by Kazemi et al identifies a potentially important mechanism for induction of aP2 in atherogenesis, namely TLR ligation.aP2 is not the only target gene by which TLR signaling modulates cellular lipid metabolism. TLR3 and TLR4 inhibit cholesterol efflux by reducing the expression of ABCA1 and several other genes.25 This is attributable to an inhibition of the transcription factor, lipid-X receptor (LXR). Of note, effects on LXR/ABCA1 were observed with ligands for TLR3 and TLR4,25 while effects on aP2 were recorded with ligands for TLR2 and TLR4 but not TLR3.21 This suggests that the crosstalk between innate immunity and lipid metabolism is complex and may involve several signal transduction pathways other than the well-known MyD88-NF-kB pathway. Indeed, the inhibition of LXR is independent of NF-κB and mediated through another transcription factor, IRF-3.25Another article published in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology adds additional pieces to the puzzle. Miller et al26 present an analysis of the signals through which mmLDL induces proinflammatory gene expression in macrophages. mmLDL induced robust phosphoinositide-3-kinase activation and ERK1/3 phosphorylation, which exceeded that caused by the TLR4 ligand LPS. In contrast, mmLDL could not trigger NF-κB activation. The pattern of induced downstream genes therefore differs between mmLDL and LPS, and it is concluded that mmLDL induces some of its effects on macrophages through TLR4 and others independently of TLR4. The components of mmLDL which trigger these different pathways remain unclear, although an oxidized phospholipid, ox-PAPC, was recently reported to target TLR4 and activate MAP kinases, but not NF-κB, in endothelial cells.27 Adding to complexity, ox-PAPC inhibits TLR4 translocation to lipid rafts, resulting in reduced signaling.28What to conclude from all this information? The tightly woven network of molecular interactions between pattern recognition receptors, intracellular and extracellular lipids, and transcription regulatory pathways has just begun to be unraveled, and many surprises are undoubtedly waiting ahead of us. But the fact that such interactions occur, on several different levels, points to the importance of lipids and lipoproteins in molecular pattern recognition and to the power of innate immunity as a regulator of metabolism.Our understanding of the clinical relevance of pattern recognition in cardiovascular disease is equally limited. Until now, focus has been on two polymorphic sites in coding regions of TLR4. The Asp299Gly and Thr399Ile polymorphisms cause hyporesponsiveness to LPS in macrophages and have been examined for their effect on atherosclerotic cardiovascular disease in several studies. The first one used ultrasonographic analysis of intima-media thickness in the common carotid artery as a surrogate marker for atherosclerosis in 810 individuals of the Bruneck study.29 55 subjects carrying the 299Gly allele had lower risk of carotid atherosclerosis and a smaller intima-media thickness than those carrying the wild-type allele. These data suggest that the hyporesponsive TLR4 allele protects against atherosclerosis and hence that TLR4 signaling is proatherosclerotic. However, a larger study using myocardial infarction as a hard end point arrived at a different conclusion.30 The 299Gly and 399Ile were significantly more common among 1213 survivors of a first myocardial infarction than in a matched control group of 1561 individuals in the Stockholm Heart Epidemiology Program (SHEEP). The reason for this discrepancy is unknown; one may speculate that TLR4-dependent activation of the AP-1 and NF-κB pathways promote smooth muscle proliferation and the formation of a stable fibrous cap.30 In the Dutch REGRESS study of myocardial infarction, 299Gly carriers had more severe coronary disease and gained more from statin treatment than those carrying the wild-type allele.31At balance, the clinical studies of TLR4 polymorphism suggest that (1) TLR4 activation promotes lesion growth; (2) it reduces the risk for myocardial infarction, possibly by promoting plaque stabilization; and (3) the TLR4 pathway interacts with statins. These findings demonstrate that innate immunity plays a role in atherosclerosis and ischemic heart disease, but we do not yet understand the precise mechanisms. The 2 studies published in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology identify molecular mechanisms that may be important in the immunopathogenesis of atherosclerosis. Therefore, they may contribute to the phenotypes observed in the epidemiological studies of cardiovascular disease. These are exciting times at the heart of immunology.FootnotesCorrespondence to Göran K. Hansson, Center for Molecular Medicine and Department of Medicine, Karolinska University Hospital L8:03 Karolinska Institute SE-17176 Stockholm, Sweden. E-mail [email protected] References 1 Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979; 76: 168–178.CrossrefGoogle Scholar2 Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 1990; 343: 531–535.CrossrefMedlineGoogle Scholar3 Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86: 973–983.CrossrefMedlineGoogle Scholar4 Gonzalez-Crespo S, Levine M. Related target enhancers for dorsal and NF-kappa B signaling pathways. Science. 1994; 264: 255–258.CrossrefMedlineGoogle Scholar5 Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997; 388: 394–397.CrossrefMedlineGoogle Scholar6 Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282: 2085–2088.CrossrefMedlineGoogle Scholar7 Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992; 13: 11–16.CrossrefMedlineGoogle Scholar8 Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol. 2001; 166: 2018–2024.CrossrefMedlineGoogle Scholar9 Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med. 1999; 5: 702–705.CrossrefMedlineGoogle Scholar10 Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002; 105: 1158–1161.LinkGoogle Scholar11 Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001; 104: 3103–3108.CrossrefMedlineGoogle Scholar12 Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003; 278: 1561–1568.CrossrefMedlineGoogle Scholar13 Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000; 164: 558–561.CrossrefMedlineGoogle Scholar14 Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002; 106: 1985–1990.LinkGoogle Scholar15 Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005; 66: 162–169.CrossrefMedlineGoogle Scholar16 Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10: 416–421.CrossrefMedlineGoogle Scholar17 Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004; 101: 10679–10684.CrossrefMedlineGoogle Scholar18 Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003; 59: 234–240.CrossrefMedlineGoogle Scholar19 Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 656–660.LinkGoogle Scholar20 Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a Th1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998; 101: 1717–1725.CrossrefMedlineGoogle Scholar21 Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol. 2005; 25: 1220–1224.LinkGoogle Scholar22 Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001; 7: 699–705.CrossrefMedlineGoogle Scholar23 Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002; 22: 1686–1691.LinkGoogle Scholar24 Perrella MA, Pellacani A, Layne MD, Patel A, Zhao D, Schreiber BM, Storch J, Feinberg MW, Hsieh CM, Haber E, Lee ME. Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice. Faseb J. 2001; 15: 1774–1776.CrossrefMedlineGoogle Scholar25 Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell. 2003; 12: 805–816.CrossrefMedlineGoogle Scholar26 Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol. 2005; 25: 1213–1219.LinkGoogle Scholar27 Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, Berliner JA. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem. 2003; 278: 29661–29666.CrossrefMedlineGoogle Scholar28 Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003; 23: 1197–1203.LinkGoogle Scholar29 Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002; 347: 185–192.CrossrefMedlineGoogle Scholar30 Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten A, Hansson GK, de Faire U, Yan ZQ. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J. 2004; 25: 1447–1453.CrossrefMedlineGoogle Scholar31 Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003; 107: 2416–2421.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Caruso G, Di Pietro L and Caraci F (2023) Gap Junctions and Connexins in Microglia-Related Oxidative Stress and Neuroinflammation: Perspectives for Drug Discovery, Biomolecules, 10.3390/biom13030505, 13:3, (505) Cerqueira O, Antunes F, Assis N, Cardoso E, Clavijo-Salomón M, Domingues A, Tessarollo N and Strauss B (2022) Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma, Frontiers in Molecular Biosciences, 10.3389/fmolb.2022.777775, 9 Kumar V and Barrett J (2022) Toll-Like Receptors (TLRs) in Health and Disease: An Overview Toll-like Receptors in Health and Disease, 10.1007/164_2021_568, (1-21), . Hu D, Lu Y, Wang D, Nie C and Li Y (2021) Glycosaminoglycan biosynthesis pathway in host genome is associated with Helicobacter pylori infection, Scientific Reports, 10.1038/s41598-021-97790-7, 11:1 Lai Y, Tsai B, Hsu C, Chen Y, Chou P, Chen Y, Liu H, Ko W, Tsai P and Hung Y (2021) The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients, Frontiers in Immunology, 10.3389/fimmu.2021.691039, 12 Mokhtari Y, Pourbagheri‐Sigaroodi A, Zafari P, Bagheri N, Ghaffari S and Bashash D (2020) Toll‐like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.16214, 25:2, (639-651), Online publication date: 1-Jan-2021. Liao A and Muyayalo K (2021) Toll-like receptors and NOD-like receptors at the implantation site Reproductive Immunology, 10.1016/B978-0-12-818508-7.00001-4, (277-294), . Vasilyeva E and Brusov O (2020) The Role of Monocytes Cellular and Molecular Mechanisms in the Development of Systemic Immune Inflammation. Part 1, Psikhiatriya, 10.30629/2618-6667-2020-18-3-76-85, 18:3, (76-85) Jagtap P, Prasad P, Pateria A, Deshmukh S and Gupta S (2020) A Single Step in vitro Bioassay Mimicking TLR4-LPS Pathway and the Role of MD2 and CD14 Coreceptors, Frontiers in Immunology, 10.3389/fimmu.2020.00005, 11 Vasilyeva E, Sekirina T, Sarmanova Z, Zozulya S, Omel'chenko M and Klushnik T (2019) ESTIMATION OF LEVEL OF SUBPOPULATION CD14+/CD16+ MONOCYTES IN PATIENTS WITH JUVENILE DEPRESSIONS, Medical Immunology (Russia), 10.15789/1563-0625-2019-2-257-268, 21:2, (257-268) Liu Y, Wei W, Hong C, Wang Y, Sun X, Ma J and Zheng F (2019) Calreticulin induced endothelial ICAM-1 up-regulation associated with tristetraprolin expression alteration through PI3K/Akt/eNOS/p38 MAPK signaling pathway in rheumatoid arthritis, Molecular Immunology, 10.1016/j.molimm.2019.01.005, 107, (10-20), Online publication date: 1-Mar-2019. Gustchina E and Williams K (2019) Limulus Ancient Innate Responses Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems, 10.1007/978-3-030-17148-3_18, (631-682), . Garaschuk O and Verkhratsky A (2019) Physiology of Microglia Microglia, 10.1007/978-1-4939-9658-2_3, (27-40), . Sun Q and Zhang X (2018) An English–Chinese termbase of neological medical terms: a corpus-based project, Lexicography, 10.1007/s40607-018-0035-0, 4:1, (23-38), Online publication date: 1-Jun-2018. Guessoum O, Tang Q, Agorsor I, Ke W, Li R, Danna C and Deppmann C (2017) TLR Signalling: Beyond Immunity eLS, 10.1002/9780470015902.a0027502, (1-7) Gankovskaya L, Khelminskaya N, Molchanova E and Svitich O (2016) ROLE OF INNATE IMMUNITY FACTORS IN PERIODONTITIS PATHOGENESIS, Journal of microbiology, epidemiology and immunobiology, 10.36233/0372-9311-2016-2-100-107, 93:2, (100-107) Paul R, Choudhury A, Choudhury S, Mazumder M and Borah A (2016) Cholesterol in Pancreatic β-Cell Death and Dysfunction, Pancreas, 10.1097/MPA.0000000000000486, 45:3, (317-324), Online publication date: 1-Mar-2016. Ray S and Banerjee A (2016) In Silico Perspective into Interactions and Mutations in Human TLR4 and Ebola Glycoprotein Applied Case Studies and Solutions in Molecular Docking-Based Drug Design, 10.4018/978-1-5225-0362-0.ch008, (209-231) Choi J, Song P and Ko Y (2016) Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker, Urogenital Tract Infection, 10.14777/uti.2016.11.1.1, 11:1, (1), . Moticka E (2016) Recognition Structures on Cells of the Innate Host Defense Mechanisms A Historical Perspective on Evidence-Based Immunology, 10.1016/B978-0-12-398381-7.00015-0, (121-128), . Chami B, Barrie N, Cai X, Wang X, Paul M, Morton-Chandra R, Sharland A, Dennis J, Freedman S and Witting P (2015) Serum Amyloid A Receptor Blockade and Incorporation into High-Density Lipoprotein Modulates Its Pro-Inflammatory and Pro-Thrombotic Activities on Vascular Endothelial Cells, International Journal of Molecular Sciences, 10.3390/ijms160511101, 16:12, (11101-11124) Bibliography Postgenomics, 10.1215/9780822375449-013, (243-279) Verkhratsky A and Parpura V (2015) Physiology of Astroglia: Channels, Receptors, Transporters, Ion Signaling and Gliotransmission, Colloquium Series on Neuroglia in Biology and Medicine: from Physiology to Disease, 10.4199/C00123ED1V01Y201501NGL004, 2:2, (1-172), Online publication date: 3-Apr-2015. Shen X (2015) High-mobility group box 1 protein and its role in severe acute pancreatitis, World Journal of Gastroenterology, 10.3748/wjg.v21.i5.1424, 21:5, (1424), . Karki K, Pande D, Negi R, Khanna S, Khanna R and Khanna H (2015) Linking Toll-Like Receptors Signaling to Oxidative Damage: Potential Role in Cancer Therapy Free Radicals in Human Health and Disease, 10.1007/978-81-322-2035-0_20, (323-334), . Halanych K and Kocot K (2014) Repurposed Transcriptomic Data Facilitate Discovery of Innate Immunity Toll-Like Receptor (TLR) Genes Across Lophotrochozoa, The Biological Bulletin, 10.1086/BBLv227n2p201, 227:2, (201-209), Online publication date: 1-Oct-2014. Bastiaansen A, Karper J, Wezel A, de Boer H, Welten S, de Jong R, Peters E, de Vries M, van Oeveren-Rietdijk A, van Zonneveld A, Hamming J, Nossent A, Quax P and Emanueli C (2014) TLR4 Accessory Molecule RP105 (CD180) Regulates Monocyte-Driven Arteriogenesis in a Murine Hind Limb Ischemia Model, PLoS ONE, 10.1371/journal.pone.0099882, 9:6, (e99882) Hurley D (2014) NEWS FROM THE AAN ANNUAL MEETING, Neurology Today, 10.1097/01.NT.0000451838.88464.08, 14:12, (28), Online publication date: 19-Jun-2014. Khan A, Aslam M, Hussain I, Naz A, Rana I, Ahmad M, Ali M and Ahmad S (2013) Role of Toll-like receptor 2 (-196 to -174) polymorphism in susceptibility to pulmonary tuberculosis in Pakistani population, International Journal of Immunogenetics, 10.1111/iji.12086, 41:2, (105-111), Online publication date: 1-Apr-2014. Holldack J (2014) Toll-like receptors as therapeutic targets for cancer, Drug Discovery Today, 10.1016/j.drudis.2013.08.020, 19:4, (379-382), Online publication date: 1-Apr-2014. Verkhratsky A and Noda M (2014) General Physiology and Pathophysiology of Microglia Neuroinflammation and Neurodegeneration, 10.1007/978-1-4939-1071-7_3, (47-60), . Noda M (2014) Possible Therapeutic Targets in Microglia Pathological Potential of Neuroglia, 10.1007/978-1-4939-0974-2_13, (293-313), . Frazão J, Errante P and Condino-Neto A (2013) Toll-Like Receptors' Pathway Disturbances are Associated with Increased Susceptibility to Infections in Humans, Archivum Immunologiae et Therapiae Experimentalis, 10.1007/s00005-013-0243-0, 61:6, (427-443), Online publication date: 1-Dec-2013. Khodadust R, Mutlu P, Yalcın S, Unsoy G and Gunduz U (2013) Polyinosinic:polycytidylic acid loading onto different generations of PAMAM dendrimer-coated magnetic nanoparticles, Journal of Nanoparticle Research, 10.1007/s11051-013-1860-6, 15:8, Online publication date: 1-Aug-2013. Hung Y, Lin H, Wu T, Liu H, Lee J, Lee C, Wu Y, Wan L, Tsai P, Ko W and Heimesaat M (2013) Risk Factors of Fecal Toxigenic or Non-Toxigenic Clostridium difficile Colonization: Impact of Toll-Like Receptor Polymorphisms and Prior Antibiotic Exposure, PLoS ONE, 10.1371/journal.pone.0069577, 8:7, (e69577) Boi S and Elsawa S (2013) Epigenetic Regulation of Toll-Like Receptor Signaling: Implications for Cancer Development, Medical Epigenetics, 10.1159/000353684, 1:1, (19-30) (2013) Microglia Glial Physiology and Pathophysiology, 10.1002/9781118402061.ch7, (343-380) Khodadust R, Unsoy G, Yalcın S, Gunduz G and Gunduz U (2013) PAMAM dendrimer-coated iron oxide nanoparticles: synthesis and characterization of different generations, Journal of Nanoparticle Research, 10.1007/s11051-013-1488-6, 15:3, Online publication date: 1-Mar-2013. Di Benedetto A, Gigante I, Colucci S and Grano M (2013) Periodontal Disease: Linking the Primary Inflammation to Bone Loss, Clinical and Developmental Immunology, 10.1155/2013/503754, 2013, (1-7), . Yang Z, Huang B, Zhang Z, Kang Y, Fu M and Liao W (2012) Effects of IL-1 Receptor-Associated Kinase-4 Gene Silencing on Human Osteoblast-Like Cells, Connective Tissue Research, 10.3109/03008207.2012.694927, 53:6, (498-507), Online publication date: 1-Dec-2012. Mutlu P, Ural A and Gündüz U (2012) Differential oncogene-related gene expressions in myeloma cells resistant to prednisone and vincristine, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2012.02.007, 66:7, (506-511), Online publication date: 1-Oct-2012. Goldsmith J and Jobin C (2012) Think Small: Zebrafish as a Model System of Human Pathology, Journal of Biomedicine and Biotechnology, 10.1155/2012/817341, 2012, (1-12), . Tompa G, Laine A, Pihlanto A, Korhonen H, Rogelj I and Marnila P (2010) Chemiluminescence of non-differentiated THP-1 promonocytes: developing an assay for screening anti-inflammatory milk proteins and peptides, Luminescence, 10.1002/bio.1220, 26:4, (251-258), Online publication date: 1-Jul-2011. Turner T, Mammen T, Kavoussi P, Lysiak J and Costabile R (2011) Cytokine Responses to E. coli-induced Epididymitis in the Rat: Blockade by Vasectomy, Urology, 10.1016/j.urology.2011.02.037, 77:6, (1507.e9-1507.e14), Online publication date: 1-Jun-2011. Karper J, de Vries M, van den Brand B, Hoefer I, Fischer J, Jukema J, Niessen H and Quax P (2011) Toll-Like Receptor 4 Is Involved in Human and Mouse Vein Graft Remodeling, and Local Gene Silencing Reduces Vein Graft Disease in Hypercholesterolemic APOE*3Leiden Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 31:5, (1033-1040), Online publication date: 1-May-2011. Arslan F, de Kleijn D and Pasterkamp G (2011) Innate immune signaling in cardiac ischemia, Nature Reviews Cardiology, 10.1038/nrcardio.2011.38, 8:5, (292-300), Online publication date: 1-May-2011. KATUNINA O (2011) Functions of Toll-like receptors as an inborn immunity component and their participation in the pathogenesis of dermatoses of different etiologies, Vestnik dermatologii i venerologii, 10.25208/vdv978, 87:2, (18-25) Kettenmann H, Hanisch U, Noda M and Verkhratsky A (2011) Physiology of Microglia, Physiological Reviews, 10.1152/physrev.00011.2010, 91:2, (461-553), Online publication date: 1-Apr-2011. Hans M and Hans V (2011) Toll-like receptors and their dual role in periodontitis: a review, Journal of Oral Science, 10.2334/josnusd.53.263, 53:3, (263-271), . Ioannou S and Voulgarelis M (2010) Toll-Like Receptors, Tissue Injury, and Tumourigenesis, Mediators of Inflammation, 10.1155/2010/581837, 2010, (1-9), . Boivin W, Cooper D, Hiebert P and Granville D (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma, Laboratory Investigation, 10.1038/labinvest.2009.91, 89:11, (1195-1220), Online publication date: 1-Nov-2009. Vitseva O, Tanriverdi K, Tchkonia T, Kirkland J, McDonnell M, Apovian C, Freedman J and Gokce N (2012) Inducible Toll-like Receptor and NF-κB Regulatory Pathway Expression in Human Adipose Tissue, Obesity, 10.1038/oby.2008.25, 16:5, (932-937), Online publication date: 1-May-2008. Levin A and Coetzee A (2014) Statins and perioperative myocardial infarction, Southern African Journal of Anaesthesia and Analgesia, 10.1080/22201173.2007.10872486, 13:3, (15-20), Online publication date: 1-May-2007. Godfraind T (2006) Calcium-channel modulators for cardiovascular disease, Expert Opinion on Emerging Drugs, 10.1517/14728214.11.1.49, 11:1, (49-73), Online publication date: 1-Mar-2006. Bornstein S and Morawietz H (2005) Toll-Like Receptors, Endocrine Stress Response, and Arteriosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 25:9, (e135-e135), Online publication date: 1-Sep-2005. June 2005Vol 25, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000168894.43759.47PMID: 15923538 Originally publishedJune 1, 2005 PDF download Advertisement
Referência(s)